A deeper look into the Edwards TAVI studies
A deeper look into the Edwards TAVI studies

Download the Edwards Balloon Expandable TAVI Compendium.

TAVI use has grown rapidly over the last decade1, due to innovations in valve prostheses and delivery systems, improvements in clinical outcomes2,3 and the 2021 ESC/EACTS Guidelines recommending TF-TAVI as preferred mode of intervention in patients ≥75 years of age*, as well as for additional patient groups < 75 years of age.The PARTNER 3 Trial further illustrates the unprecedented outcomes of TAVI for low-risk patients.5

Access detailed information of the TAVI clinical studies by Edwards Lifesciences.

*Based on evaluation of clinical, anatomical and procedural factors


1    Biasco L, Ferrari E, Pedrazzini G, et al. Front Cardiovasc Med. 2018;5:88.

2    Neylon A, Ahmed K, Mercanti F, et al. J Thorac Dis. 2018;10(Suppl 30):S3637–S3645.

3    Rheude T, Blumenstein J, Möllmann H, et al. Med Devices (Auckl). 2018;11:353–360.

4    Vahanian A, et al. Eur Heart J. 2021; ehab395. doi:10.1093/eurheartj/ehab395.

5    Mack MJ, Leon MB, Thourani VH, et al. Transcatheter aortic-valve replacement with a balloon-expandable valve in low- risk patients. N Engl J Med. 2019;380(18):1695-1705.

For professional use. For a listing of indications, contraindications, precautions, warnings, and potential adverse events, please refer to the Instructions for Use (consult eifu.edwards.com where applicable). Edwards devices placed on the European market meeting the essential requirements referred to in Article 3 of the Medical Device Directive 93/42/EEC bear the CE marking of conformity.

PP—EU-4087 v1.0

Help us create better content with 3 short questions.

Content relating to Tavi.today is intended for healthcare professionals. Click OK to confirm you are a healthcare professional and proceed.
Skip to content